Many modules are hidden in this stack. Use "module --show_hidden spider SOFTWARE" if you are not able to find the required software
# packages in environment at /cluster/home/gcardenal/miniconda3/envs/vllm:
#
# Name                    Version                   Build  Channel
_libgcc_mutex             0.1                        main  
_openmp_mutex             5.1                       1_gnu  
accelerate                1.1.1                    pypi_0    pypi
aiohappyeyeballs          2.4.0                    pypi_0    pypi
aiohttp                   3.10.6                   pypi_0    pypi
aiosignal                 1.3.1                    pypi_0    pypi
annotated-types           0.7.0                    pypi_0    pypi
anthropic                 0.40.0                   pypi_0    pypi
anyio                     4.6.0                    pypi_0    pypi
argon2-cffi               23.1.0                   pypi_0    pypi
argon2-cffi-bindings      21.2.0                   pypi_0    pypi
arrow                     1.3.0                    pypi_0    pypi
asttokens                 3.0.0                    pypi_0    pypi
async-lru                 2.0.4                    pypi_0    pypi
async-timeout             4.0.3                    pypi_0    pypi
attrs                     24.2.0                   pypi_0    pypi
babel                     2.16.0                   pypi_0    pypi
beautifulsoup4            4.12.3                   pypi_0    pypi
bleach                    6.2.0                    pypi_0    pypi
bzip2                     1.0.8                h5eee18b_6  
ca-certificates           2024.7.2             h06a4308_0  
certifi                   2024.8.30                pypi_0    pypi
cffi                      1.17.1                   pypi_0    pypi
charset-normalizer        3.3.2                    pypi_0    pypi
click                     8.1.7                    pypi_0    pypi
cloudpickle               3.0.0                    pypi_0    pypi
comm                      0.2.2                    pypi_0    pypi
datasets                  3.0.1                    pypi_0    pypi
debugpy                   1.8.9                    pypi_0    pypi
decorator                 5.1.1                    pypi_0    pypi
defusedxml                0.7.1                    pypi_0    pypi
dill                      0.3.8                    pypi_0    pypi
diskcache                 5.6.3                    pypi_0    pypi
distro                    1.9.0                    pypi_0    pypi
einops                    0.8.0                    pypi_0    pypi
emoji                     2.14.0                   pypi_0    pypi
exceptiongroup            1.2.2                    pypi_0    pypi
executing                 2.1.0                    pypi_0    pypi
fastapi                   0.115.0                  pypi_0    pypi
fastjsonschema            2.21.1                   pypi_0    pypi
filelock                  3.16.1                   pypi_0    pypi
fqdn                      1.5.1                    pypi_0    pypi
frozenlist                1.4.1                    pypi_0    pypi
fsspec                    2024.6.1                 pypi_0    pypi
gguf                      0.10.0                   pypi_0    pypi
h11                       0.14.0                   pypi_0    pypi
httpcore                  1.0.5                    pypi_0    pypi
httptools                 0.6.1                    pypi_0    pypi
httpx                     0.27.2                   pypi_0    pypi
huggingface-hub           0.25.1                   pypi_0    pypi
idna                      3.10                     pypi_0    pypi
importlib-metadata        8.5.0                    pypi_0    pypi
interegular               0.3.3                    pypi_0    pypi
ipykernel                 6.29.5                   pypi_0    pypi
ipython                   8.30.0                   pypi_0    pypi
ipywidgets                8.1.5                    pypi_0    pypi
isoduration               20.11.0                  pypi_0    pypi
jedi                      0.19.2                   pypi_0    pypi
jinja2                    3.1.4                    pypi_0    pypi
jiter                     0.5.0                    pypi_0    pypi
json5                     0.10.0                   pypi_0    pypi
jsonpointer               3.0.0                    pypi_0    pypi
jsonschema                4.23.0                   pypi_0    pypi
jsonschema-specifications 2023.12.1                pypi_0    pypi
jupyter                   1.1.1                    pypi_0    pypi
jupyter-client            8.6.3                    pypi_0    pypi
jupyter-console           6.6.3                    pypi_0    pypi
jupyter-core              5.7.2                    pypi_0    pypi
jupyter-events            0.10.0                   pypi_0    pypi
jupyter-lsp               2.2.5                    pypi_0    pypi
jupyter-server            2.14.2                   pypi_0    pypi
jupyter-server-terminals  0.5.3                    pypi_0    pypi
jupyterlab                4.3.2                    pypi_0    pypi
jupyterlab-pygments       0.3.0                    pypi_0    pypi
jupyterlab-server         2.27.3                   pypi_0    pypi
jupyterlab-widgets        3.0.13                   pypi_0    pypi
lark                      1.2.2                    pypi_0    pypi
ld_impl_linux-64          2.40                 h12ee557_0  
libffi                    3.4.4                h6a678d5_1  
libgcc-ng                 11.2.0               h1234567_1  
libgomp                   11.2.0               h1234567_1  
libstdcxx-ng              11.2.0               h1234567_1  
libuuid                   1.41.5               h5eee18b_0  
llvmlite                  0.43.0                   pypi_0    pypi
lm-format-enforcer        0.10.6                   pypi_0    pypi
markupsafe                2.1.5                    pypi_0    pypi
matplotlib-inline         0.1.7                    pypi_0    pypi
mistral-common            1.4.3                    pypi_0    pypi
mistune                   3.0.2                    pypi_0    pypi
mpmath                    1.3.0                    pypi_0    pypi
msgpack                   1.1.0                    pypi_0    pypi
msgspec                   0.18.6                   pypi_0    pypi
multidict                 6.1.0                    pypi_0    pypi
multiprocess              0.70.16                  pypi_0    pypi
nbclient                  0.10.1                   pypi_0    pypi
nbconvert                 7.16.4                   pypi_0    pypi
nbformat                  5.10.4                   pypi_0    pypi
ncurses                   6.4                  h6a678d5_0  
nest-asyncio              1.6.0                    pypi_0    pypi
networkx                  3.3                      pypi_0    pypi
notebook                  7.3.1                    pypi_0    pypi
notebook-shim             0.2.4                    pypi_0    pypi
numba                     0.60.0                   pypi_0    pypi
numpy                     1.26.4                   pypi_0    pypi
nvidia-cublas-cu12        12.1.3.1                 pypi_0    pypi
nvidia-cuda-cupti-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-nvrtc-cu12    12.1.105                 pypi_0    pypi
nvidia-cuda-runtime-cu12  12.1.105                 pypi_0    pypi
nvidia-cudnn-cu12         9.1.0.70                 pypi_0    pypi
nvidia-cufft-cu12         11.0.2.54                pypi_0    pypi
nvidia-curand-cu12        10.3.2.106               pypi_0    pypi
nvidia-cusolver-cu12      11.4.5.107               pypi_0    pypi
nvidia-cusparse-cu12      12.1.0.106               pypi_0    pypi
nvidia-ml-py              12.560.30                pypi_0    pypi
nvidia-nccl-cu12          2.20.5                   pypi_0    pypi
nvidia-nvjitlink-cu12     12.6.68                  pypi_0    pypi
nvidia-nvtx-cu12          12.1.105                 pypi_0    pypi
openai                    1.48.0                   pypi_0    pypi
openssl                   3.0.15               h5eee18b_0  
outlines                  0.0.46                   pypi_0    pypi
overrides                 7.7.0                    pypi_0    pypi
packaging                 24.1                     pypi_0    pypi
pandas                    2.2.3                    pypi_0    pypi
pandocfilters             1.5.1                    pypi_0    pypi
parso                     0.8.4                    pypi_0    pypi
partial-json-parser       0.2.1.1.post4            pypi_0    pypi
pexpect                   4.9.0                    pypi_0    pypi
pillow                    10.4.0                   pypi_0    pypi
pip                       24.2            py310h06a4308_0  
platformdirs              4.3.6                    pypi_0    pypi
plotly                    5.24.1                   pypi_0    pypi
prometheus-client         0.21.0                   pypi_0    pypi
prometheus-fastapi-instrumentator 7.0.0                    pypi_0    pypi
prompt-toolkit            3.0.48                   pypi_0    pypi
protobuf                  5.28.2                   pypi_0    pypi
psutil                    6.0.0                    pypi_0    pypi
ptyprocess                0.7.0                    pypi_0    pypi
pure-eval                 0.2.3                    pypi_0    pypi
py-cpuinfo                9.0.0                    pypi_0    pypi
pyairports                2.1.1                    pypi_0    pypi
pyarrow                   17.0.0                   pypi_0    pypi
pycountry                 24.6.1                   pypi_0    pypi
pycparser                 2.22                     pypi_0    pypi
pydantic                  2.9.2                    pypi_0    pypi
pydantic-core             2.23.4                   pypi_0    pypi
pygments                  2.18.0                   pypi_0    pypi
python                    3.10.14              h955ad1f_1  
python-dateutil           2.9.0.post0              pypi_0    pypi
python-dotenv             1.0.1                    pypi_0    pypi
python-json-logger        2.0.7                    pypi_0    pypi
pytz                      2024.2                   pypi_0    pypi
pyyaml                    6.0.2                    pypi_0    pypi
pyzmq                     26.2.0                   pypi_0    pypi
ray                       2.37.0                   pypi_0    pypi
readline                  8.2                  h5eee18b_0  
referencing               0.35.1                   pypi_0    pypi
regex                     2024.9.11                pypi_0    pypi
requests                  2.32.3                   pypi_0    pypi
rfc3339-validator         0.1.4                    pypi_0    pypi
rfc3986-validator         0.1.1                    pypi_0    pypi
rpds-py                   0.20.0                   pypi_0    pypi
safetensors               0.4.5                    pypi_0    pypi
send2trash                1.8.3                    pypi_0    pypi
sentencepiece             0.2.0                    pypi_0    pypi
setuptools                75.1.0          py310h06a4308_0  
six                       1.16.0                   pypi_0    pypi
sniffio                   1.3.1                    pypi_0    pypi
soupsieve                 2.6                      pypi_0    pypi
sqlite                    3.45.3               h5eee18b_0  
stack-data                0.6.3                    pypi_0    pypi
stanza                    1.9.2                    pypi_0    pypi
starlette                 0.38.6                   pypi_0    pypi
sympy                     1.13.3                   pypi_0    pypi
tenacity                  9.0.0                    pypi_0    pypi
terminado                 0.18.1                   pypi_0    pypi
tiktoken                  0.7.0                    pypi_0    pypi
timm                      1.0.12                   pypi_0    pypi
tinycss2                  1.4.0                    pypi_0    pypi
tk                        8.6.14               h39e8969_0  
tokenizers                0.20.0                   pypi_0    pypi
tomli                     2.2.1                    pypi_0    pypi
torch                     2.4.0                    pypi_0    pypi
torchvision               0.19.0                   pypi_0    pypi
tornado                   6.4.2                    pypi_0    pypi
tqdm                      4.66.5                   pypi_0    pypi
traitlets                 5.14.3                   pypi_0    pypi
transformers              4.45.0                   pypi_0    pypi
triton                    3.0.0                    pypi_0    pypi
types-python-dateutil     2.9.0.20241003           pypi_0    pypi
typing-extensions         4.12.2                   pypi_0    pypi
tzdata                    2024.2                   pypi_0    pypi
uri-template              1.3.0                    pypi_0    pypi
urllib3                   2.2.3                    pypi_0    pypi
uvicorn                   0.30.6                   pypi_0    pypi
uvloop                    0.20.0                   pypi_0    pypi
vllm                      0.6.2                    pypi_0    pypi
watchfiles                0.24.0                   pypi_0    pypi
wcwidth                   0.2.13                   pypi_0    pypi
webcolors                 24.11.1                  pypi_0    pypi
webencodings              0.5.1                    pypi_0    pypi
websocket-client          1.8.0                    pypi_0    pypi
websockets                13.1                     pypi_0    pypi
wheel                     0.44.0          py310h06a4308_0  
widgetsnbextension        4.0.13                   pypi_0    pypi
xformers                  0.0.27.post2             pypi_0    pypi
xxhash                    3.5.0                    pypi_0    pypi
xz                        5.4.6                h5eee18b_1  
yarl                      1.12.1                   pypi_0    pypi
zipp                      3.20.2                   pypi_0    pypi
zlib                      1.2.13               h5eee18b_1  
Package                           Version
--------------------------------- --------------
accelerate                        1.1.1
aiohappyeyeballs                  2.4.0
aiohttp                           3.10.6
aiosignal                         1.3.1
annotated-types                   0.7.0
anthropic                         0.40.0
anyio                             4.6.0
argon2-cffi                       23.1.0
argon2-cffi-bindings              21.2.0
arrow                             1.3.0
asttokens                         3.0.0
async-lru                         2.0.4
async-timeout                     4.0.3
attrs                             24.2.0
babel                             2.16.0
beautifulsoup4                    4.12.3
bleach                            6.2.0
certifi                           2024.8.30
cffi                              1.17.1
charset-normalizer                3.3.2
click                             8.1.7
cloudpickle                       3.0.0
comm                              0.2.2
datasets                          3.0.1
debugpy                           1.8.9
decorator                         5.1.1
defusedxml                        0.7.1
dill                              0.3.8
diskcache                         5.6.3
distro                            1.9.0
einops                            0.8.0
emoji                             2.14.0
exceptiongroup                    1.2.2
executing                         2.1.0
fastapi                           0.115.0
fastjsonschema                    2.21.1
filelock                          3.16.1
fqdn                              1.5.1
frozenlist                        1.4.1
fsspec                            2024.6.1
gguf                              0.10.0
h11                               0.14.0
httpcore                          1.0.5
httptools                         0.6.1
httpx                             0.27.2
huggingface-hub                   0.25.1
idna                              3.10
importlib_metadata                8.5.0
interegular                       0.3.3
ipykernel                         6.29.5
ipython                           8.30.0
ipywidgets                        8.1.5
isoduration                       20.11.0
jedi                              0.19.2
Jinja2                            3.1.4
jiter                             0.5.0
json5                             0.10.0
jsonpointer                       3.0.0
jsonschema                        4.23.0
jsonschema-specifications         2023.12.1
jupyter                           1.1.1
jupyter_client                    8.6.3
jupyter-console                   6.6.3
jupyter_core                      5.7.2
jupyter-events                    0.10.0
jupyter-lsp                       2.2.5
jupyter_server                    2.14.2
jupyter_server_terminals          0.5.3
jupyterlab                        4.3.2
jupyterlab_pygments               0.3.0
jupyterlab_server                 2.27.3
jupyterlab_widgets                3.0.13
lark                              1.2.2
llvmlite                          0.43.0
lm-format-enforcer                0.10.6
MarkupSafe                        2.1.5
matplotlib-inline                 0.1.7
mistral_common                    1.4.3
mistune                           3.0.2
mpmath                            1.3.0
msgpack                           1.1.0
msgspec                           0.18.6
multidict                         6.1.0
multiprocess                      0.70.16
nbclient                          0.10.1
nbconvert                         7.16.4
nbformat                          5.10.4
nest-asyncio                      1.6.0
networkx                          3.3
notebook                          7.3.1
notebook_shim                     0.2.4
numba                             0.60.0
numpy                             1.26.4
nvidia-cublas-cu12                12.1.3.1
nvidia-cuda-cupti-cu12            12.1.105
nvidia-cuda-nvrtc-cu12            12.1.105
nvidia-cuda-runtime-cu12          12.1.105
nvidia-cudnn-cu12                 9.1.0.70
nvidia-cufft-cu12                 11.0.2.54
nvidia-curand-cu12                10.3.2.106
nvidia-cusolver-cu12              11.4.5.107
nvidia-cusparse-cu12              12.1.0.106
nvidia-ml-py                      12.560.30
nvidia-nccl-cu12                  2.20.5
nvidia-nvjitlink-cu12             12.6.68
nvidia-nvtx-cu12                  12.1.105
openai                            1.48.0
outlines                          0.0.46
overrides                         7.7.0
packaging                         24.1
pandas                            2.2.3
pandocfilters                     1.5.1
parso                             0.8.4
partial-json-parser               0.2.1.1.post4
pexpect                           4.9.0
pillow                            10.4.0
pip                               24.2
platformdirs                      4.3.6
plotly                            5.24.1
prometheus_client                 0.21.0
prometheus-fastapi-instrumentator 7.0.0
prompt_toolkit                    3.0.48
protobuf                          5.28.2
psutil                            6.0.0
ptyprocess                        0.7.0
pure_eval                         0.2.3
py-cpuinfo                        9.0.0
pyairports                        2.1.1
pyarrow                           17.0.0
pycountry                         24.6.1
pycparser                         2.22
pydantic                          2.9.2
pydantic_core                     2.23.4
Pygments                          2.18.0
python-dateutil                   2.9.0.post0
python-dotenv                     1.0.1
python-json-logger                2.0.7
pytz                              2024.2
PyYAML                            6.0.2
pyzmq                             26.2.0
ray                               2.37.0
referencing                       0.35.1
regex                             2024.9.11
requests                          2.32.3
rfc3339-validator                 0.1.4
rfc3986-validator                 0.1.1
rpds-py                           0.20.0
safetensors                       0.4.5
Send2Trash                        1.8.3
sentencepiece                     0.2.0
setuptools                        75.1.0
six                               1.16.0
sniffio                           1.3.1
soupsieve                         2.6
stack-data                        0.6.3
stanza                            1.9.2
starlette                         0.38.6
sympy                             1.13.3
tenacity                          9.0.0
terminado                         0.18.1
tiktoken                          0.7.0
timm                              1.0.12
tinycss2                          1.4.0
tokenizers                        0.20.0
tomli                             2.2.1
torch                             2.4.0
torchvision                       0.19.0
tornado                           6.4.2
tqdm                              4.66.5
traitlets                         5.14.3
transformers                      4.45.0
triton                            3.0.0
types-python-dateutil             2.9.0.20241003
typing_extensions                 4.12.2
tzdata                            2024.2
uri-template                      1.3.0
urllib3                           2.2.3
uvicorn                           0.30.6
uvloop                            0.20.0
vllm                              0.6.2
watchfiles                        0.24.0
wcwidth                           0.2.13
webcolors                         24.11.1
webencodings                      0.5.1
websocket-client                  1.8.0
websockets                        13.1
wheel                             0.44.0
widgetsnbextension                4.0.13
xformers                          0.0.27.post2
xxhash                            3.5.0
yarl                              1.12.1
zipp                              3.20.2

Currently Loaded Modules:
  1) eth_proxy      4) stack/2024-06   7) python/3.11.6  10) openblas/0.3.24
  2) julia/1.10.3   5) r/4.3.2         8) cuda/12.1.1    11) python_cuda/3.11.6
  3) gcc/12.2.0     6) hdf5/1.14.3     9) nccl/2.18.3-1

 

Testing Slurm Variables...
SLURM_JOB_USER=gcardenal
SLURM_TASKS_PER_NODE=1
SLURM_JOB_UID=608619
SLURM_TASK_PID=2880086
SLURM_JOB_GPUS=3,9
SLURM_LOCALID=0
SLURM_SUBMIT_DIR=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation
SLURMD_NODENAME=eu-a65-06
SLURM_JOB_START_TIME=1737117958
SLURM_CLUSTER_NAME=euler-24-production
SLURM_JOB_END_TIME=1737132358
SLURM_CPUS_ON_NODE=8
SLURM_JOB_CPUS_PER_NODE=8
SLURM_GPUS_ON_NODE=2
SLURM_GTIDS=0
SLURM_JOB_PARTITION=gpupr.4h
SLURM_TRES_PER_TASK=cpu=8
SLURM_JOB_NUM_NODES=1
SLURM_JOBID=21058700
SLURM_GPUS=nvidia_a100_80gb_pcie:2
SLURM_JOB_QOS=es_ilic/gpupr/4
SLURM_PROCID=0
SLURM_CPUS_PER_TASK=8
SLURM_NTASKS=1
SLURM_TOPOLOGY_ADDR=.euler_a100_80_lca_ib.eu-a65-06
SLURM_TOPOLOGY_ADDR_PATTERN=switch.switch.node
SLURM_MEM_PER_CPU=10240
SLURM_SCRIPT_CONTEXT=prolog_task
SLURM_NODELIST=eu-a65-06
SLURM_JOB_ACCOUNT=gpupr/es_ilic
SLURM_PRIO_PROCESS=0
SLURM_NPROCS=1
SLURM_NNODES=1
SLURM_SUBMIT_HOST=eu-g5-030-1
SLURM_JOB_ID=21058700
SLURM_NODEID=0
SLURM_CONF=/cluster/slurm/adm/etc/slurm.conf
SLURM_JOB_NAME=llama_no_api
SLURM_JOB_GID=492010
SLURM_JOB_NODELIST=eu-a65-06
Fri Jan 17 13:46:11 2025       
+-----------------------------------------------------------------------------------------+
| NVIDIA-SMI 550.127.08             Driver Version: 550.127.08     CUDA Version: 12.4     |
|-----------------------------------------+------------------------+----------------------+
| GPU  Name                 Persistence-M | Bus-Id          Disp.A | Volatile Uncorr. ECC |
| Fan  Temp   Perf          Pwr:Usage/Cap |           Memory-Usage | GPU-Util  Compute M. |
|                                         |                        |               MIG M. |
|=========================================+========================+======================|
|   0  NVIDIA A100 80GB PCIe          On  |   00000000:48:00.0 Off |                    0 |
| N/A   51C    P0             45W /  300W |       1MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
|   1  NVIDIA A100 80GB PCIe          On  |   00000000:CD:00.0 Off |                    0 |
| N/A   49C    P0             46W /  300W |       1MiB /  81920MiB |      0%      Default |
|                                         |                        |             Disabled |
+-----------------------------------------+------------------------+----------------------+
                                                                                         
+-----------------------------------------------------------------------------------------+
| Processes:                                                                              |
|  GPU   GI   CI        PID   Type   Process name                              GPU Memory |
|        ID   ID                                                               Usage      |
|=========================================================================================|
|  No running processes found                                                             |
+-----------------------------------------------------------------------------------------+
Node IP: 10.205.9.15
JobId=21058700 JobName=llama_no_api
   UserId=gcardenal(608619) GroupId=gcardenal-group(492010) MCS_label=N/A
   Priority=5808 Nice=0 Account=gpupr/es_ilic QOS=es_ilic/gpupr/4
   JobState=RUNNING Reason=None Dependency=(null)
   Requeue=0 Restarts=0 BatchFlag=1 Reboot=0 ExitCode=0:0
   RunTime=00:00:14 TimeLimit=04:00:00 TimeMin=N/A
   SubmitTime=2025-01-17T13:11:18 EligibleTime=2025-01-17T13:11:18
   AccrueTime=2025-01-17T13:11:18
   StartTime=2025-01-17T13:45:58 EndTime=2025-01-17T17:45:58 Deadline=N/A
   SuspendTime=None SecsPreSuspend=0 LastSchedEval=2025-01-17T13:45:58 Scheduler=Main
   Partition=gpupr.4h AllocNode:Sid=eu-g5-030-1:27237
   ReqNodeList=(null) ExcNodeList=(null)
   NodeList=eu-a65-06
   BatchHost=eu-a65-06
   NumNodes=1 NumCPUs=8 NumTasks=1 CPUs/Task=8 ReqB:S:C:T=0:0:*:*
   ReqTRES=cpu=8,mem=80G,node=1,billing=347340,gres/gpu=2,gres/gpu:nvidia_a100_80gb_pcie=2,gres/gpumem=85899345920
   AllocTRES=cpu=8,mem=80G,node=1,billing=347340,gres/gpu=2,gres/gpu:nvidia_a100_80gb_pcie=2,gres/gpumem=0
   Socks/Node=* NtasksPerN:B:S:C=0:0:*:1 CoreSpec=*
   MinCPUsNode=8 MinMemoryCPU=10G MinTmpDiskNode=0
   Features=(null) DelayBoot=00:00:00
   OverSubscribe=OK Contiguous=0 Licenses=(null) Network=(null)
   Command=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/generate_answers.sh
   WorkDir=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation
   StdErr=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/llama_no_api21058700.out
   StdIn=/dev/null
   StdOut=/cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/llama_no_api21058700.out
   TresPerJob=gres/gpu:nvidia_a100_80gb_pcie:2
   TresPerNode=gres/gpumem:80G
   TresPerTask=cpu=8
   

Running in standalone mode...
I0117 13:46:15.059000 22693303187264 torch/distributed/run.py:859] 
I0117 13:46:15.059000 22693303187264 torch/distributed/run.py:859] **************************************
I0117 13:46:15.059000 22693303187264 torch/distributed/run.py:859] Rendezvous info:
I0117 13:46:15.059000 22693303187264 torch/distributed/run.py:859] --rdzv-backend=c10d --rdzv-endpoint=localhost:0 --rdzv-id=2630aff5-a662-4c68-8b37-f97b633c044a
I0117 13:46:15.059000 22693303187264 torch/distributed/run.py:859] **************************************
I0117 13:46:15.059000 22693303187264 torch/distributed/run.py:859] 
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188] Starting elastic_operator with launch configs:
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   entrypoint       : get_model_answers_and_prompt_generation.py
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   min_nodes        : 1
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   max_nodes        : 1
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   nproc_per_node   : 1
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   run_id           : 2630aff5-a662-4c68-8b37-f97b633c044a
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   rdzv_backend     : c10d
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   rdzv_endpoint    : localhost:0
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   rdzv_configs     : {'timeout': 900}
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   max_restarts     : 0
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   monitor_interval : 5
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   log_dir          : /scratch/tmp.21058700.gcardenal/torchelastic_no7pj2af
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188]   metrics_cfg      : {}
I0117 13:46:15.060000 22693303187264 torch/distributed/launcher/api.py:188] 
I0117 13:46:15.072000 22693303187264 torch/distributed/elastic/agent/server/api.py:866] [default] starting workers for entrypoint: python3
I0117 13:46:15.072000 22693303187264 torch/distributed/elastic/agent/server/api.py:699] [default] Rendezvous'ing worker group
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568] [default] Rendezvous complete for workers. Result:
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   restart_count=0
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   master_addr=eu-a65-06.euler.ethz.ch
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   master_port=33663
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   group_rank=0
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   group_world_size=1
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   local_ranks=[0]
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   role_ranks=[0]
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   global_ranks=[0]
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   role_world_sizes=[1]
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568]   global_world_sizes=[1]
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:568] 
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/api.py:707] [default] Starting worker group
I0117 13:46:15.201000 22693303187264 torch/distributed/elastic/agent/server/local_elastic_agent.py:168] Environment variable 'TORCHELASTIC_ENABLE_FILE_TIMER' not found. Do not start FileTimerServer.
I0117 13:46:15.202000 22693303187264 torch/distributed/elastic/multiprocessing/api.py:263] log directory set to: /scratch/tmp.21058700.gcardenal/torchelastic_no7pj2af/2630aff5-a662-4c68-8b37-f97b633c044a_ar60bn78
I0117 13:46:15.202000 22693303187264 torch/distributed/elastic/multiprocessing/api.py:358] Setting worker0 reply file to: /scratch/tmp.21058700.gcardenal/torchelastic_no7pj2af/2630aff5-a662-4c68-8b37-f97b633c044a_ar60bn78/attempt_0/0/error.json
2025-01-17 13:46:20.666860: E external/local_xla/xla/stream_executor/cuda/cuda_dnn.cc:9261] Unable to register cuDNN factory: Attempting to register factory for plugin cuDNN when one has already been registered
2025-01-17 13:46:20.666907: E external/local_xla/xla/stream_executor/cuda/cuda_fft.cc:607] Unable to register cuFFT factory: Attempting to register factory for plugin cuFFT when one has already been registered
2025-01-17 13:46:20.668319: E external/local_xla/xla/stream_executor/cuda/cuda_blas.cc:1515] Unable to register cuBLAS factory: Attempting to register factory for plugin cuBLAS when one has already been registered
2025-01-17 13:46:20.674338: I tensorflow/core/platform/cpu_feature_guard.cc:182] This TensorFlow binary is optimized to use available CPU instructions in performance-critical operations.
To enable the following instructions: AVX2 FMA, in other operations, rebuild TensorFlow with the appropriate compiler flags.
2025-01-17 13:46:22.005923: W tensorflow/compiler/tf2tensorrt/utils/py_utils.cc:38] TF-TRT Warning: Could not find TensorRT
API call for Llama failed with error: Connection error.
Falling back to local Llama inference - Loading model...
Loading checkpoint shards:   0%|                                                          | 0/30 [00:00<?, ?it/s]Loading checkpoint shards:   3%|█▋                                                | 1/30 [00:57<27:44, 57.39s/it]Loading checkpoint shards:   7%|███▎                                              | 2/30 [02:15<32:20, 69.30s/it]Loading checkpoint shards:  10%|█████                                             | 3/30 [03:30<32:31, 72.28s/it]Loading checkpoint shards:  13%|██████▋                                           | 4/30 [03:40<20:35, 47.51s/it]Loading checkpoint shards:  17%|████████▎                                         | 5/30 [04:26<19:37, 47.09s/it]Loading checkpoint shards:  20%|██████████                                        | 6/30 [05:33<21:33, 53.90s/it]Loading checkpoint shards:  23%|███████████▋                                      | 7/30 [05:40<14:41, 38.32s/it]Loading checkpoint shards:  27%|█████████████▎                                    | 8/30 [05:48<10:33, 28.79s/it]Loading checkpoint shards:  30%|███████████████                                   | 9/30 [05:53<07:26, 21.26s/it]Loading checkpoint shards:  33%|████████████████▎                                | 10/30 [05:58<05:29, 16.46s/it]Loading checkpoint shards:  37%|█████████████████▉                               | 11/30 [06:06<04:23, 13.88s/it]Loading checkpoint shards:  40%|███████████████████▌                             | 12/30 [06:11<03:17, 10.98s/it]Loading checkpoint shards:  43%|█████████████████████▏                           | 13/30 [07:08<07:02, 24.86s/it]Loading checkpoint shards:  47%|██████████████████████▊                          | 14/30 [07:19<05:32, 20.76s/it]Loading checkpoint shards:  50%|████████████████████████▌                        | 15/30 [07:36<04:53, 19.59s/it]Loading checkpoint shards:  53%|██████████████████████████▏                      | 16/30 [07:39<03:26, 14.75s/it]Loading checkpoint shards:  57%|███████████████████████████▊                     | 17/30 [07:46<02:40, 12.32s/it]Loading checkpoint shards:  60%|█████████████████████████████▍                   | 18/30 [08:51<05:38, 28.18s/it]Loading checkpoint shards:  63%|███████████████████████████████                  | 19/30 [09:10<04:38, 25.31s/it]Loading checkpoint shards:  67%|████████████████████████████████▋                | 20/30 [09:15<03:12, 19.27s/it]Loading checkpoint shards:  70%|██████████████████████████████████▎              | 21/30 [09:20<02:16, 15.15s/it]Loading checkpoint shards:  73%|███████████████████████████████████▉             | 22/30 [09:29<01:44, 13.07s/it]Loading checkpoint shards:  77%|█████████████████████████████████████▌           | 23/30 [10:26<03:03, 26.24s/it]Loading checkpoint shards:  80%|███████████████████████████████████████▏         | 24/30 [10:35<02:07, 21.26s/it]Loading checkpoint shards:  83%|████████████████████████████████████████▊        | 25/30 [10:57<01:47, 21.41s/it]Loading checkpoint shards:  87%|██████████████████████████████████████████▍      | 26/30 [11:13<01:19, 19.91s/it]Loading checkpoint shards:  90%|████████████████████████████████████████████     | 27/30 [11:17<00:45, 15.12s/it]Loading checkpoint shards:  93%|█████████████████████████████████████████████▋   | 28/30 [11:23<00:24, 12.27s/it]Loading checkpoint shards:  97%|███████████████████████████████████████████████▎ | 29/30 [11:35<00:12, 12.15s/it]Loading checkpoint shards: 100%|█████████████████████████████████████████████████| 30/30 [11:38<00:00,  9.32s/it]Loading checkpoint shards: 100%|█████████████████████████████████████████████████| 30/30 [11:38<00:00, 23.27s/it]
Starting inference for question locally (Llama): How is HIV diagnosed?
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nHow is HIV diagnosed?<|eot_id|>assistant\n\nHIV (Human Immunodeficiency Virus) diagnosis involves a combination of medical history, physical examination, and laboratory tests. Here's an overview of the diagnostic process:\n\n**Screening Tests:**\n\n1. **Rapid Tests**: These are point-of-care tests that provide quick results, usually within 20-30 minutes. They detect the presence of HIV antibodies or antigens in blood or oral fluid. Examples include OraQuick and Uni-Gold.\n2. **Enzyme-Linked Immunosorbent Assay (ELISA)**: This is a laboratory-based test that detects HIV antibodies in blood. It's often used as an initial screening test.\n\n**Confirmatory Tests:**\n\n1. **Western Blot**: This test is used to confirm a positive ELISA result. It detects the presence of specific HIV antibodies and is more specific than ELISA.\n2. **Polymerase Chain Reaction (PCR)**: This test detects the genetic material of the virus (RNA or DNA) in blood. It's often used to confirm a diagnosis in infants born to HIV-positive mothers or in individuals with suspected early infection.\n3. **Nucleic Acid Amplification Test (NAAT)**: This test detects the genetic material of the virus (RNA or DNA) in blood. It's similar to PCR and is used to confirm a diagnosis.\n\n**Diagnostic Algorithm:**\n\n1. **Initial Screening**: A rapid test or ELISA is performed to detect HIV antibodies or antigens.\n2. **Confirmatory Testing**: If the initial screening test is positive, a confirmatory test (Western Blot, PCR, or NAAT) is performed to confirm the diagnosis.\n3. **Repeat Testing**: If the confirmatory test is positive, a repeat test is performed to rule out false positives.\n4. **CD4 Cell Count and Viral Load Testing**: Once a diagnosis is confirmed, CD4 cell count and viral load tests are performed to assess the stage of infection and guide treatment.\n\n**Special Considerations:**\n\n1. **Early Infection**: In the early stages of infection, the virus may not be detectable by antibody tests. In such cases, PCR or NAAT may be used to detect the virus.\n2. **Infants and Children**: HIV diagnosis in infants and children requires specialized testing, such as PCR or NAAT, as they may not produce antibodies until several months after birth.\n3. **False Negatives**: False-negative results can occur if testing is done too early after exposure or if the individual has a weakened immune system.\n\nIt's essential to note that HIV diagnosis should only be performed by a qualified healthcare professional, and results should be interpreted in the context of the individual's medical history and risk factors."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What are the different stages of HIV?
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nWhat are the different stages of HIV?<|eot_id|>assistant\n\nHIV (Human Immunodeficiency Virus) infection progresses through several stages, which can be divided into four main stages: Acute HIV Infection, Clinical Latency, AIDS (Acquired Immunodeficiency Syndrome), and the final stage, which is also AIDS. Here's an overview of each stage:\n\n**Stage 1: Acute HIV Infection (2-4 weeks after exposure)**\n\n* This is the initial stage of HIV infection, which occurs when the virus first enters the body.\n* During this stage, the virus multiplies rapidly, and the person may experience flu-like symptoms, such as fever, fatigue, and swollen lymph nodes.\n* The viral load (the amount of virus in the blood) is high, making the person highly infectious.\n* The body's immune system responds to the infection, and antibodies against HIV are produced.\n\n**Stage 2: Clinical Latency (also known as Chronic HIV Infection)**\n\n* This stage can last for many years, during which the virus is still active, but the person may not show any symptoms.\n* The viral load is lower than during the acute stage, but the virus is still present in the body.\n* The immune system is able to keep the virus under control, but it is not able to eliminate it.\n* People in this stage can still transmit the virus to others.\n\n**Stage 3: Symptomatic HIV Infection (also known as AIDS-Related Complex)**\n\n* This stage occurs when the immune system is weakened, and the virus starts to cause symptoms.\n* The person may experience symptoms such as weight loss, diarrhea, fever, and swollen lymph nodes.\n* The viral load increases, and the person becomes more infectious.\n* This stage is a sign that the disease is progressing, and treatment is necessary to prevent further damage to the immune system.\n\n**Stage 4: AIDS (Acquired Immunodeficiency Syndrome)**\n\n* This is the final stage of HIV infection, which occurs when the immune system is severely damaged.\n* The person is highly susceptible to opportunistic infections (OIs) and cancers, such as pneumonia, tuberculosis, and Kaposi's sarcoma.\n* The viral load is very high, and the person is highly infectious.\n* Without treatment, AIDS can lead to death.\n\nIt's essential to note that with antiretroviral therapy (ART), people with HIV can manage the disease and prevent it from progressing to AIDS. ART can suppress the virus, allowing the immune system to recover and reducing the risk of transmission to others. Early diagnosis and treatment are crucial in preventing the progression of HIV to AIDS."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How is HIV transmitted?
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nHow is HIV transmitted?<|eot_id|>assistant\n\nHIV (Human Immunodeficiency Virus) is a virus that attacks the body's immune system. It is transmitted through certain bodily fluids from a person who has a detectable viral load and is not taking antiretroviral therapy (ART) or is not virally suppressed. The primary ways HIV is transmitted are:\n\n1. **Sexual contact**: HIV can be transmitted through vaginal, anal, or oral sex without the use of a condom or other barrier method. The risk of transmission is higher during anal sex, as the lining of the rectum is more fragile and prone to bleeding.\n2. **Blood-to-blood contact**: HIV can be transmitted through:\n\t* Sharing needles or syringes contaminated with infected blood.\n\t* Blood transfusions (although this is extremely rare in countries with strict blood screening programs).\n\t* Organ transplantation from an infected donor (although this is also extremely rare).\n3. **Mother-to-child transmission**: HIV can be transmitted from an infected mother to her child during:\n\t* Pregnancy (through the placenta).\n\t* Childbirth (through exposure to infected blood and vaginal fluids).\n\t* Breastfeeding (through breast milk).\n4. **Occupational exposure**: Healthcare workers may be at risk of HIV transmission through:\n\t* Accidental needlesticks or cuts with contaminated needles.\n\t* Exposure to infected blood or other bodily fluids through mucous membranes (e.g., eyes, mouth).\n\nIt's essential to note that HIV is NOT transmitted through:\n\n* Casual contact (e.g., hugging, shaking hands, sharing food or drinks).\n* Air or water.\n* Insect bites.\n* Saliva, sweat, or tears (unless these fluids are mixed with blood).\n* Toilet seats, door handles, or other surfaces.\n\nTo prevent HIV transmission, it's crucial to:\n\n* Practice safe sex (use condoms or other barrier methods).\n* Avoid sharing needles or syringes.\n* Get tested regularly for HIV and other STIs.\n* Take antiretroviral therapy (ART) if you're living with HIV to achieve viral suppression.\n* Follow proper infection control procedures in healthcare settings.\n\nRemember, knowledge is power! Educate yourself and others about HIV transmission and prevention to help reduce the spread of the virus."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What comorbidities are common among people living 
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nWhat comorbidities are common among people living with HIV?<|eot_id|>assistant\n\nPeople living with HIV (PLWH) are at increased risk of developing various comorbidities, which are health conditions that occur simultaneously with HIV infection. Some common comorbidities among PLWH include:\n\n1. **Mental health disorders**: Depression, anxiety, post-traumatic stress disorder (PTSD), and substance use disorders are common among PLWH.\n2. **Cardiovascular disease**: PLWH are at higher risk of cardiovascular disease, including heart attacks, strokes, and high blood pressure, due to inflammation and antiretroviral therapy (ART) side effects.\n3. **Chronic kidney disease**: HIV infection and ART can damage the kidneys, increasing the risk of chronic kidney disease and end-stage renal disease.\n4. **Hepatitis B and C co-infection**: PLWH are at higher risk of co-infection with hepatitis B and C, which can lead to liver disease and liver cancer.\n5. **Cancer**: PLWH are at increased risk of various cancers, including:\n\t* Kaposi's sarcoma\n\t* Non-Hodgkin lymphoma\n\t* Hodgkin lymphoma\n\t* Lung cancer\n\t* Liver cancer\n\t* Anal cancer\n\t* Cervical cancer\n6. **Osteoporosis**: PLWH are at higher risk of osteoporosis, particularly those with advanced HIV disease or taking certain ART regimens.\n7. **Diabetes**: PLWH are at increased risk of developing type 2 diabetes, particularly those taking certain ART regimens or with a family history of diabetes.\n8. **Lipodystrophy**: PLWH may experience lipodystrophy, a condition characterized by abnormal fat distribution, which can lead to metabolic complications.\n9. **Neurological disorders**: PLWH are at higher risk of neurological disorders, including:\n\t* HIV-associated neurocognitive disorder (HAND)\n\t* Seizures\n\t* Stroke\n\t* Peripheral neuropathy\n10. **Gastrointestinal disorders**: PLWH may experience gastrointestinal disorders, such as:\n\t* Gastroesophageal reflux disease (GERD)\n\t* Peptic ulcer disease\n\t* Inflammatory bowel disease (IBD)\n11. **Respiratory diseases**: PLWH are at higher risk of respiratory diseases, including:\n\t* Chronic obstructive pulmonary disease (COPD)\n\t* Pneumonia\n\t* Tuberculosis (TB)\n12. **Dental and oral health issues**: PLWH may experience dental and oral health issues, such as:\n\t* Periodontal disease\n\t* Oral candidiasis (thrush)\n\t* Dental caries\n\nIt's essential for PLWH to work closely with their healthcare providers to manage these comorbidities and prevent complications. Regular health check-ups, screenings, and adherence to ART can help mitigate the risk of developing these comorbidities."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How can HIV be prevented?
<class 'dict'> {'generated_text': '<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nHow can HIV be prevented?<|eot_id|>assistant\n\nHIV (Human Immunodeficiency Virus) can be prevented through a combination of strategies that reduce the risk of transmission. Here are some effective ways to prevent HIV:\n\n1. **Abstinence**: Not having sex or intimate contact with someone who has HIV is the most effective way to prevent transmission.\n2. **Condom use**: Using condoms consistently and correctly during vaginal, anal, and oral sex can significantly reduce the risk of HIV transmission.\n3. **Mutual monogamy**: Being in a long-term, mutually monogamous relationship with someone who has been tested for HIV and is not infected can reduce the risk of transmission.\n4. **Pre-exposure prophylaxis (PrEP)**: Taking antiretroviral medication daily can help prevent HIV infection in people who are at high risk of exposure, such as those who have multiple sex partners or inject drugs.\n5. **Post-exposure prophylaxis (PEP)**: Taking antiretroviral medication within 72 hours of potential exposure to HIV can help prevent infection.\n6. **HIV testing and counseling**: Getting tested for HIV regularly and knowing your status can help you take steps to prevent transmission to others.\n7. **Safe injection practices**: Using sterile needles and syringes, and not sharing equipment, can reduce the risk of HIV transmission among people who inject drugs.\n8. **Vaccination**: Getting vaccinated against other sexually transmitted infections (STIs) like hepatitis B and human papillomavirus (HPV) can also reduce the risk of HIV transmission.\n9. **Reducing number of sex partners**: Having fewer sex partners can reduce the risk of HIV transmission.\n10. **Avoiding shared personal items**: Not sharing personal items like razors, toothbrushes, or nail clippers can reduce the risk of HIV transmission.\n11. **HIV treatment as prevention**: People living with HIV who are on antiretroviral therapy (ART) and have an undetectable viral load have a significantly reduced risk of transmitting the virus to others.\n12. **Male circumcision**: Male circumcision has been shown to reduce the risk of HIV transmission in men by up to 60%.\n13. **Harm reduction programs**: Participating in harm reduction programs, such as needle exchange programs, can reduce the risk of HIV transmission among people who inject drugs.\n14. **Sex education and awareness**: Educating oneself and others about HIV transmission, prevention, and treatment can help reduce the risk of transmission.\n15. **Regular medical check-ups**: Regular medical check-ups and screenings can help identify HIV infection early, and treatment can be initiated to prevent transmission to others.\n\nRemember, HIV prevention is a shared responsibility, and it requires a combination of individual and community-based efforts to reduce the risk of transmission.'}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How frequently ART must be taken?
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nHow frequently ART must be taken?<|eot_id|>assistant\n\nAntiretroviral Therapy (ART) is typically taken daily, and the frequency can vary depending on the specific medication regimen. Most people with HIV take a combination of medications, usually 1-3 pills, once or twice a day.\n\nThe most common dosing schedules for ART are:\n\n1. **Once-daily**: One pill or a combination of pills taken once a day, usually in the morning or evening.\n2. **Twice-daily**: One or more pills taken twice a day, usually in the morning and evening, with a 12-hour gap in between.\n3. **Fixed-dose combination**: A single pill that contains multiple medications, taken once or twice a day.\n\nIt's essential to take ART as prescribed by your healthcare provider, without missing doses or stopping treatment, to:\n\n* Maintain viral suppression\n* Prevent drug resistance\n* Keep the immune system strong\n* Reduce the risk of transmission to others\n\nIf you have any concerns or questions about your ART regimen, be sure to discuss them with your healthcare provider. They can help you understand your treatment plan and provide guidance on how to manage any side effects or challenges."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How can we prevent Perinatal transmission of HIV?
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nHow can we prevent Perinatal transmission of HIV?<|eot_id|>assistant\n\nPreventing perinatal transmission of HIV (mother-to-child transmission) is crucial to reduce the risk of HIV infection in newborns. Here are the effective ways to prevent perinatal transmission of HIV:\n\n1. **Antiretroviral Therapy (ART)**: Providing ART to HIV-positive pregnant women during pregnancy, childbirth, and breastfeeding can significantly reduce the risk of transmission. ART suppresses the viral load, making it less likely for the virus to be transmitted to the baby.\n2. **Prenatal Care**: Regular prenatal care allows for early detection of HIV infection and initiation of ART. It also enables healthcare providers to monitor the woman's viral load and adjust treatment as needed.\n3. **HIV Testing**: Universal HIV testing for all pregnant women is essential to identify those who are HIV-positive and provide them with appropriate care and treatment.\n4. **Elective Cesarean Delivery**: For women with high viral loads (above 1000 copies/mL) near the time of delivery, elective cesarean delivery can reduce the risk of transmission.\n5. **Avoidance of Breastfeeding**: HIV-positive women should avoid breastfeeding their babies, as HIV can be transmitted through breast milk. Formula feeding is recommended instead.\n6. **Antiretroviral Prophylaxis**: Administering antiretroviral medication to the newborn within the first few hours of life can help prevent HIV infection.\n7. **Post-Exposure Prophylaxis (PEP)**: If a baby is born to an HIV-positive mother and was not exposed to ART during pregnancy, PEP can be administered to the baby within 72 hours of birth to reduce the risk of transmission.\n8. **Pre-Exposure Prophylaxis (PrEP)**: PrEP can be used by HIV-negative women who are at high risk of acquiring HIV during pregnancy or breastfeeding to prevent infection.\n9. **Male Circumcision**: Male circumcision has been shown to reduce the risk of HIV transmission from mother to child.\n10. **Education and Counseling**: Educating HIV-positive women about the risks of perinatal transmission and the importance of adherence to ART and other preventive measures can help reduce the risk of transmission.\n\nBy implementing these strategies, the risk of perinatal transmission of HIV can be significantly reduced, and the number of children born with HIV can be decreased. According to the World Health Organization (WHO), the implementation of these interventions has led to a significant decline in mother-to-child transmission of HIV, from 400,000 cases in 2009 to 160,000 cases in 2020."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What are the main cell types infected with HIV?
<class 'dict'> {'generated_text': '<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nWhat are the main cell types infected with HIV?<|eot_id|>assistant\n\nThe main cell types infected with HIV (Human Immunodeficiency Virus) are:\n\n1. **CD4+ T cells** (also known as T helper cells): These cells play a crucial role in the immune system, helping to coordinate the response to infections. HIV binds to the CD4 receptor on the surface of these cells, allowing the virus to enter and replicate.\n2. **Macrophages**: These cells are a type of white blood cell that engulfs and digests foreign particles and microorganisms. Macrophages can also be infected with HIV, which can lead to the production of new viral particles.\n3. **Dendritic cells**: These cells are antigen-presenting cells that help to activate T cells and initiate an immune response. Dendritic cells can also be infected with HIV, which can facilitate the spread of the virus to other cells.\n\nThese cell types are the primary targets of HIV infection, and the virus uses various mechanisms to infect and replicate within them. The infection of CD4+ T cells is particularly significant, as it can lead to a decline in the number of these cells, which is a hallmark of HIV infection and AIDS (Acquired Immune Deficiency Syndrome).'}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What is the difference between HIV and AIDS?
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nWhat is the difference between HIV and AIDS?<|eot_id|>assistant\n\nHIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) are two related but distinct conditions.\n\n**HIV:**\nHIV is a virus that attacks the body's immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections. When HIV infects these cells, it weakens the immune system, making it harder for the body to fight off infections and diseases. HIV is a chronic and manageable condition, and with proper treatment, people with HIV can live long and healthy lives.\n\n**AIDS:**\nAIDS is the most advanced stage of HIV infection. It occurs when the HIV virus has severely damaged the immune system, leaving the body vulnerable to opportunistic infections and cancers. AIDS is characterized by a severely weakened immune system, which makes it difficult for the body to fight off infections and diseases. AIDS is a life-threatening condition, but with proper treatment, it can be managed and controlled.\n\n**Key differences:**\n\n1. **HIV is the virus, while AIDS is the condition**: HIV is the virus that causes AIDS, but not everyone with HIV has AIDS.\n2. **HIV is a chronic condition, while AIDS is a life-threatening condition**: With proper treatment, HIV can be managed and controlled, while AIDS requires more intensive treatment and can be life-threatening if left untreated.\n3. **HIV can be asymptomatic, while AIDS is characterized by symptoms**: People with HIV may not show any symptoms for years, while people with AIDS typically experience symptoms such as weight loss, diarrhea, and opportunistic infections.\n4. **HIV can be transmitted, while AIDS is not directly transmitted**: HIV can be transmitted through bodily fluids, such as blood, semen, and breast milk, while AIDS is not directly transmitted from person to person.\n\n**Stages of HIV infection:**\n\n1. **Acute HIV infection**: The initial stage of HIV infection, which can last for several weeks or months.\n2. **Chronic HIV infection**: The long-term stage of HIV infection, which can last for years or even decades.\n3. **AIDS**: The most advanced stage of HIV infection, characterized by a severely weakened immune system and opportunistic infections.\n\nIt's essential to note that with proper treatment, people with HIV can prevent the progression to AIDS and live long and healthy lives. Early diagnosis, antiretroviral therapy (ART), and regular medical care can significantly improve the quality of life for people living with HIV."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): How is HIV not transmitted?
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nHow is HIV not transmitted?<|eot_id|>assistant\n\nHIV (Human Immunodeficiency Virus) is not transmitted through the following means:\n\n1. **Casual contact**: Shaking hands, hugging, or casual kissing does not transmit HIV.\n2. **Air or water**: HIV is not transmitted through the air, water, or by breathing the same air as someone with HIV.\n3. **Insect bites**: Mosquitoes, ticks, and other insects do not transmit HIV.\n4. **Food and drink**: Sharing food, drinks, or utensils with someone with HIV does not transmit the virus.\n5. **Toilet seats and handles**: HIV is not transmitted through contact with toilet seats, handles, or other surfaces.\n6. **Sweat, tears, and saliva**: HIV is not transmitted through sweat, tears, or saliva, unless these bodily fluids are mixed with blood or other infectious bodily fluids.\n7. **Coughing and sneezing**: HIV is not transmitted through coughing or sneezing, unless the person with HIV has a bleeding wound or lesion in their mouth or throat.\n8. **Sharing personal items**: Sharing personal items like razors, toothbrushes, or hair clippers does not transmit HIV, unless they are contaminated with blood or other infectious bodily fluids.\n9. **Swimming pools and hot tubs**: HIV is not transmitted through swimming pools or hot tubs, as the virus is not viable in water and is killed by chlorine and other disinfectants.\n10. **Vaccinations and medical procedures**: HIV is not transmitted through vaccinations, blood transfusions, or medical procedures, as long as proper infection control measures are followed.\n\nIt's essential to remember that HIV is primarily transmitted through:\n\n* Unprotected sex (vaginal, anal, or oral) with an infected person\n* Sharing needles or syringes with an infected person\n* Mother-to-child transmission during pregnancy, childbirth, or breastfeeding (if the mother is not receiving effective treatment)\n\nIf you have concerns about HIV transmission or want to know more about prevention and testing, consult a healthcare professional or a trusted resource, such as the Centers for Disease Control and Prevention (CDC) or the World Health Organization (WHO)."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What is known about the switch that occurs between
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nWhat is known about the switch that occurs between patients with latent HIV and active infection?<|eot_id|>assistant\n\nThe switch from latent HIV infection to active infection is a complex process that is not yet fully understood. However, research has shed some light on the mechanisms involved. Here's a summary of what is known:\n\n**Latent HIV infection:**\nLatent HIV infection is characterized by the presence of transcriptionally silent proviral DNA in infected cells, primarily in CD4+ T cells. During latency, the virus is not actively replicating, and the infected cells are not producing new viral particles. This state can persist for years, even decades, without symptoms.\n\n**Reactivation of latent HIV:**\nThe switch from latency to active infection is thought to occur when the latent virus is reactivated, allowing the virus to start replicating again. Several factors can trigger reactivation, including:\n\n1. **Immune activation**: Activation of the immune system, such as during an opportunistic infection or inflammation, can reactivate latent HIV.\n2. **Cytokine signaling**: Cytokines, such as TNF-α and IL-1β, can stimulate the reactivation of latent HIV.\n3. **Cellular stress**: Cellular stress, such as that caused by DNA damage or oxidative stress, can also trigger reactivation.\n4. **Epigenetic changes**: Epigenetic modifications, such as histone modifications and DNA methylation, can influence the expression of latent HIV and contribute to reactivation.\n\n**Mechanisms of reactivation:**\nThe reactivation of latent HIV involves the following steps:\n\n1. **Transcriptional activation**: The latent proviral DNA is transcribed into RNA, allowing the virus to start producing new viral particles.\n2. **Post-transcriptional regulation**: The newly transcribed RNA is processed and translated into proteins, which are then assembled into new viral particles.\n3. **Viral replication**: The new viral particles are released from the infected cell and can infect other cells, leading to the spread of the infection.\n\n**Key players:**\nSeveral cellular and viral factors play a crucial role in the switch from latency to active infection, including:\n\n1. **Tat protein**: The Tat protein is a viral transcription factor that regulates the expression of HIV genes and is essential for the reactivation of latent HIV.\n2. **NF-κB**: The NF-κB transcription factor is a key regulator of immune responses and is involved in the reactivation of latent HIV.\n3. **HDACs**: Histone deacetylases (HDACs) are enzymes that regulate chromatin structure and are involved in the maintenance of latency. Inhibitors of HDACs, such as vorinostat, have been shown to reactivate latent HIV.\n\n**Implications for therapy:**\nUnderstanding the mechanisms of latent HIV reactivation is crucial for the development of effective therapies aimed at curing HIV infection. Strategies to reactivate latent HIV, such as the use of latency-reversing agents (LRAs), are being explored as a potential approach to eliminate the latent reservoir and achieve a functional cure. However, more research is needed to fully understand the complex interactions between the virus, the host immune system, and the cellular environment that govern the switch from latency to active infection."}
Saved Llama answers (category=1, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/Llama_cluster/Llama_answers_category_1.1_HIV_EQ.json
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 58-year-old woman with HIV infection is brought 
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/μL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?<|eot_id|>assistant\n\nThe most likely diagnosis for this patient is Primary Central Nervous System Lymphoma (PCNSL).\n\nHere's a breakdown of the key points that lead to this diagnosis:\n\n1. **Immunocompromised state**: The patient has HIV infection with a low CD4+ T-lymphocyte count (90/μL), indicating a compromised immune system. This increases her susceptibility to opportunistic infections and malignancies, including PCNSL.\n\n2. **Clinical presentation**: Symptoms such as headaches, blurred vision, confusion, ataxia, and memory impairment suggest central nervous system involvement. These symptoms are consistent with a space-occupying lesion in the brain.\n\n3. **Cerebrospinal fluid (CSF) analysis**: The presence of lymphocytic predominant pleocytosis (an increase in lymphocytes in the CSF) is indicative of an inflammatory or malignant process within the central nervous system.\n\n4. **PCR positive for Epstein-Barr virus (EBV) DNA**: EBV is associated with PCNSL, especially in immunocompromised patients. The detection of EBV DNA in the CSF supports the diagnosis of PCNSL, as EBV is found in the tumor cells of most AIDS-related PCNSL cases.\n\n5. **MRI findings**: The description of a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum is typical for PCNSL. These lesions are often periventricular and can involve the corpus callosum, basal ganglia, or other deep brain structures.\n\n6. **Antiretroviral therapy and trimethoprim-sulfamethoxazole**: While these medications are crucial for managing HIV infection and preventing opportunistic infections like Pneumocystis jirovecii pneumonia, they do not directly influence the development of PCNSL but are part of the patient's background treatment.\n\nGiven these points, the combination of clinical presentation, imaging findings, CSF analysis, and the patient's immunocompromised state due to HIV infection, the most likely diagnosis is Primary Central Nervous System Lymphoma (PCNSL), which is a known complication in patients with advanced HIV disease."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 25-year-old sexually active male presents to an 
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?<|eot_id|>assistant\n\nThe medication that acts on the gp41 subunit of the HIV envelope glycoprotein is Enfuvirtide (T-20), also known as Fuzeon. However, this is not typically a first-line treatment for HIV.\n\nA more commonly prescribed medication that targets the gp41 subunit is a class of drugs called HIV fusion inhibitors, but specifically, the one that is more commonly used is Enfuvirtide's successor, which is not as commonly used due to its injectable formulation.\n\nA more commonly used oral medication that targets the HIV envelope is not exactly what is asked, however, the gp41 subunit is also targeted by an oral medication called Trogarzo (ibalizumab is an intravenous monoclonal antibody), but there is an oral medication that targets the gp41 subunit indirectly by binding to the host cell, and that is Maraviroc, but the one that targets the gp41 subunit directly is not typically the first line.\n\nThe answer to this question is actually Enfuvirtide (T-20), but it is worth noting that this is not typically the first-line treatment for HIV, and more commonly used medications are part of the first-line treatment regimens such as Integrase strand transfer inhibitors (InSTIs) like Raltegravir, Elvitegravir, Dolutegravir, or Biktarvy, or a combination of two NRTIs and a third agent, which could be a PI, NNRTI, or InSTI."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A mother with HIV has given birth to a healthy boy
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA mother with HIV has given birth to a healthy boy 2 days ago. She takes her antiretroviral medication regularly and is compliant with the therapy. Before being discharged, her doctor explains that she cannot breastfeed the child since there is a risk of infection through breastfeeding and stresses that the child can benefit from formula feeding. The physician stresses the importance of not overheating the formula since Vitamin C may be inactivated by overheating. What molecular process could be impaired if the mother boiled the formula longer than needed?<|eot_id|>assistant\n\nIf the mother boiled the formula longer than needed, the molecular process that could be impaired is denaturation of proteins and degradation of vitamins, particularly Vitamin C (ascorbic acid). \n\nVitamin C is a heat-labile and water-soluble vitamin, meaning it can be easily destroyed by heat, water, or oxygen. When formula is overheated, the Vitamin C molecules can undergo oxidation, hydrolysis, or other chemical reactions that break down the molecule, leading to its inactivation.\n\nIn particular, the heat can cause the Vitamin C molecule to undergo a process called thermal degradation, where the molecule breaks down into smaller, inactive compounds. This can result in a loss of the vitamin's biological activity and nutritional value.\n\nAdditionally, overheating the formula can also cause denaturation of proteins, which can affect their structure and function. Proteins are complex molecules that have a specific three-dimensional shape, and heat can cause them to unwind and lose their native conformation. This can lead to a loss of protein function and nutritional value.\n\nIt's worth noting that the World Health Organization (WHO) recommends boiling water for 1 minute to kill bacteria and other microorganisms, and then letting it cool down before mixing it with formula. This can help minimize the risk of overheating and preserve the nutritional value of the formula."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 35-year-old woman presents to a physician’s offi
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA 35-year-old woman presents to a physician’s office for a follow-up visit. She recently underwent a complete physical examination with routine laboratory tests. She also had a Pap smear and testing for sexually transmitted diseases. Since her divorce 2 years ago, she had sexual encounters with random men at bars or social events and frequently did not use any form of protection during sexual intercourse. She was shown to be positive for the human immunodeficiency virus (HIV). Combination anti-retroviral treatment is initiated including zidovudine, didanosine, and efavirenz. One week later, she is rushed to the hospital where she is diagnosed with acute pancreatitis. What precautions in her medication will be required after pancreatitis resolves with treatment?<|eot_id|>assistant\n\nThe patient in this scenario is being treated with a combination of antiretroviral medications for HIV, which includes zidovudine, didanosine, and efavirenz. However, she developed acute pancreatitis, a known side effect of certain antiretroviral medications.\n\nDidanosine is a nucleoside reverse transcriptase inhibitor (NRTI) known to have a higher risk of causing pancreatitis compared to other antiretroviral medications. Given that the patient developed acute pancreatitis while on this medication, it is likely that didanosine is the culprit.\n\nTo manage this patient's HIV treatment after the pancreatitis resolves, the following precautions and changes in her medication regimen should be considered:\n\n1. **Discontinue Didanosine**: Given the association between didanosine and pancreatitis, it is recommended to discontinue this medication to prevent further risk of pancreatitis.\n\n2. **Alternative NRTI**: The patient's antiretroviral regimen should be modified to replace didanosine with an alternative NRTI that has a lower risk of pancreatitis, such as tenofovir, emtricitabine, or abacavir, provided there are no other contraindications.\n\n3. **Monitor for Pancreatitis Symptoms**: Even after switching medications, the patient should be closely monitored for any signs or symptoms of pancreatitis, as some antiretroviral medications may still pose a risk, albeit lower.\n\n4. **Regular Laboratory Tests**: Regular monitoring of pancreatic enzymes (amylase and lipase) and other relevant laboratory tests should be performed to quickly identify any potential issues related to pancreatitis.\n\n5. **Patient Education**: The patient should be educated on the risks associated with her medications, the importance of adherence to the new regimen, and the need to promptly report any symptoms that could indicate pancreatitis or other side effects.\n\nBy taking these precautions and adjusting her medication regimen, the risk of recurrent pancreatitis can be minimized while effectively managing her HIV infection."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A physician scientist is looking for a more effici
<class 'dict'> {'generated_text': '<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?<|eot_id|>assistant\n\nTo determine the most likely target of the antibody being designed by the physician scientist, we need to consider the HIV envelope proteins that are commonly targeted by the natural humoral immune response. The HIV envelope is composed of two main proteins: gp120 and gp41.\n\n1. **gp120 (glycoprotein 120)**: This protein is located on the surface of the HIV envelope and plays a crucial role in the attachment of the virus to the host cell. It binds to the CD4 receptor on T cells, which is the primary receptor for HIV entry. gp120 is highly immunogenic, meaning it is very effective at triggering an immune response, including the production of antibodies. Due to its role in viral entry and its immunogenic nature, gp120 is a primary target for neutralizing antibodies, which are antibodies that can prevent the virus from infecting cells.\n\n2. **gp41 (glycoprotein 41)**: This protein is also part of the HIV envelope and works in conjunction with gp120. After gp120 binds to the CD4 receptor, gp41 undergoes a conformational change that facilitates the fusion of the viral envelope with the host cell membrane, allowing the virus to release its genetic material into the host cell. While gp41 is also a target for antibodies, the region of gp41 that is exposed and accessible to antibodies after the initial binding of gp120 to CD4 is somewhat limited, making it a less common target for neutralizing antibodies compared to gp120.\n\nGiven the critical role of gp120 in the initial stages of HIV infection and its high immunogenicity, **gp120 is the most likely target of the antibody being designed** by the physician scientist. Targeting gp120 could potentially lead to the development of a potent antibody that can neutralize HIV by preventing the virus from attaching to and entering host cells, thereby offering a more efficient way to treat HIV infection.'}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 50-year-old HIV-positive male presents to the ER
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?<|eot_id|>assistant\n\nBased on the clinical presentation and biopsy findings, the most likely causal organism is Aspergillus.\n\nHere's the reasoning:\n\n1. **HIV-positive status**: Immunocompromised patients, such as those with HIV, are more susceptible to opportunistic infections, including fungal infections like aspergillosis.\n2. **Fever and hemoptysis**: These symptoms are consistent with a pulmonary infection, and hemoptysis (coughing up blood) is a classic symptom of aspergillosis.\n3. **Fibrocavitary lesion on chest radiograph**: This type of lesion is characteristic of aspergillosis, particularly in immunocompromised patients.\n4. **Biopsy showing septate hyphae that branch at acute angles**: This is a hallmark feature of Aspergillus species. The septate hyphae (hyphae with visible septa) and acute-angle branching are distinctive characteristics that distinguish Aspergillus from other fungi, such as Mucorales (which have non-septate hyphae and right-angle branching).\n\nAspergillus is a common cause of opportunistic infections in immunocompromised patients, and the clinical and histopathological findings in this case are consistent with invasive aspergillosis."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 43-year-old man with HIV infection comes to the 
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3–4 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?<|eot_id|>assistant\n\nThe addition of valganciclovir to the patient's current medication regimen, which includes zidovudine, lamivudine, and dolutegravir, puts the patient at greatest risk for hematologic adverse effects, particularly neutropenia. \n\nValganciclovir, an antiviral medication used to treat cytomegalovirus (CMV) infections, can cause bone marrow suppression, leading to decreased production of blood cells, including neutrophils (a type of white blood cell important for fighting infections). Zidovudine, a nucleoside reverse transcriptase inhibitor (NRTI) used in antiretroviral therapy for HIV, is also known to cause bone marrow suppression and neutropenia as a side effect.\n\nThe concurrent use of valganciclovir and zidovudine increases the risk of additive or synergistic hematologic toxicity, particularly neutropenia, due to their overlapping side effect profiles. This is because both drugs can independently affect the bone marrow's ability to produce blood cells, and their combined use may exacerbate this effect.\n\nMonitoring of the patient's complete blood count (CBC) is essential during the treatment with valganciclovir and zidovudine to promptly identify and manage any signs of hematologic toxicity, such as neutropenia."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 28-year-old G1P0 woman at 16 weeks estimated ges
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient’s concern?<|eot_id|>assistant\n\nFor a newborn suspected of being exposed to HIV, the most appropriate diagnostic test would be the HIV DNA PCR (Polymerase Chain Reaction) test, also known as the HIV nucleic acid amplification test (NAAT). This test detects the genetic material of the virus itself, rather than the antibodies produced in response to the virus.\n\nThe HIV DNA PCR test is the preferred test for diagnosing HIV infection in infants because:\n\n1. **It can detect HIV infection earlier**: HIV DNA PCR can detect the virus as early as 1-2 weeks after birth, whereas antibody tests may not be reliable until 12-18 months of age.\n2. **It is more accurate**: HIV DNA PCR is highly sensitive and specific, reducing the risk of false-negative or false-positive results.\n3. **It can distinguish between maternal and infant infection**: Since infants born to HIV-positive mothers may have maternal antibodies, the HIV DNA PCR test can help determine whether the infant is actually infected or just carrying maternal antibodies.\n\nThe American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC) recommend HIV DNA PCR testing for all infants born to HIV-positive mothers, with the first test performed at 14-21 days of age, followed by additional tests at 1-2 months and 4-6 months of age.\n\nIn this scenario, the HIV DNA PCR test would be the most appropriate diagnostic test to address the patient's concern about the possible transmission of HIV to her baby."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 32-year-old man comes to the office for a routin
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?<|eot_id|>assistant\n\nThis is a classic ethical dilemma in medicine, pitting patient confidentiality against the duty to protect others from harm. The most appropriate next step by the physician would be to:\n\n1. **Counsel the patient about the risks of not disclosing his HIV status to his wife**: The physician should explain to the patient the risks of HIV transmission to his wife and the importance of disclosure to prevent harm to her. The physician should emphasize the patient's responsibility to inform his wife about his HIV status.\n\n2. **Encourage the patient to disclose his HIV status to his wife**: The physician should encourage the patient to disclose his HIV status to his wife, emphasizing the importance of honesty and the potential consequences of not disclosing.\n\n3. **Offer to facilitate disclosure or provide resources for counseling**: If the patient is unwilling or unable to disclose his HIV status to his wife, the physician can offer to facilitate disclosure or provide resources for counseling to help the patient disclose his status.\n\n4. **Notify public health authorities (if required by law)**: Depending on the jurisdiction, the physician may be required to report the patient's HIV diagnosis to public health authorities. This can help track the spread of the disease and prevent further transmission.\n\n5. **Respect patient confidentiality (but not at the expense of harming others)**: While the physician has a duty to maintain patient confidentiality, this duty is not absolute. If the patient refuses to disclose his HIV status to his wife and the physician believes that the wife is at risk of harm, the physician may need to take further action to protect her.\n\n**What not to do**:\n\n* The physician should not disclose the patient's HIV status to his wife without his consent, as this would be a breach of patient confidentiality.\n* The physician should not threaten to disclose the patient's HIV status to his wife as a means of coercing him into disclosure, as this could be seen as unethical and potentially harmful to the patient.\n\nUltimately, the physician's primary responsibility is to protect the health and well-being of all patients, including the patient's wife. If the patient refuses to disclose his HIV status to his wife and the physician believes that she is at risk of harm, the physician may need to take further action, such as notifying public health authorities or seeking guidance from a medical ethics committee."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 41-year-old HIV-positive male presents to the ER
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA 41-year-old HIV-positive male presents to the ER with a 4-day history of headaches and nuchal rigidity. A lumbar puncture shows an increase in CSF protein and a decrease in CSF glucose. When stained with India ink, light microscopy of the patient’s CSF reveals encapsulated yeast with narrow-based buds. Assuming a single pathogenic organism is responsible for this patient’s symptoms, what diagnostic test results would also be expected in this patient?<|eot_id|>assistant\n\nBased on the clinical presentation and laboratory findings, the patient is likely suffering from cryptococcal meningitis, caused by the fungus Cryptococcus neoformans. The key diagnostic features that support this diagnosis are:\n\n1. **Encapsulated yeast with narrow-based buds on India ink stain**: This is a characteristic feature of Cryptococcus neoformans.\n2. **Increased CSF protein and decreased CSF glucose**: These findings are consistent with a fungal or bacterial meningitis.\n3. **Headaches and nuchal rigidity**: These symptoms are typical of meningitis.\n\nGiven this diagnosis, the following diagnostic test results would also be expected:\n\n1. **Cryptococcal antigen (CrAg) test**: This test would likely be positive in both the CSF and serum, as it detects the capsular polysaccharide antigen of Cryptococcus neoformans.\n2. **CSF culture**: Fungal culture of the CSF would likely grow Cryptococcus neoformans, although this may take several days to weeks.\n3. **CD4 count**: As an HIV-positive patient, the CD4 count would likely be low, indicating a compromised immune system and increased susceptibility to opportunistic infections like cryptococcal meningitis.\n4. **MRI or CT scan of the head**: Imaging studies may show signs of increased intracranial pressure, such as hydrocephalus or cerebral edema, which can be complications of cryptococcal meningitis.\n\nIt's worth noting that other diagnostic tests, such as PCR (polymerase chain reaction) or molecular testing, may also be used to support the diagnosis of cryptococcal meningitis. However, the combination of clinical presentation, India ink stain, and CrAg test results would be highly suggestive of this diagnosis."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama):  What would be the best methodological approach to
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nWhat would be the best methodological approach to study microRNAs as therapeutic targets in HIV patients?<|eot_id|>assistant\n\nStudying microRNAs (miRNAs) as therapeutic targets in HIV patients requires a comprehensive and multi-disciplinary approach. Here's a suggested methodological framework:\n\n**Research Design:**\n\n1. **Literature Review**: Conduct a thorough review of existing research on miRNAs in HIV infection, including their role in viral replication, immune response, and disease progression.\n2. **Hypothesis Generation**: Based on the literature review, formulate hypotheses on specific miRNAs that could be targeted for therapeutic intervention in HIV patients.\n3. **Study Design**: Design a study to investigate the expression and functional role of selected miRNAs in HIV-infected individuals, using a combination of in vitro, in vivo, and clinical approaches.\n\n**In Vitro Studies:**\n\n1. **Cell Culture Models**: Use relevant cell lines (e.g., T cells, macrophages, dendritic cells) to study the effects of miRNA modulation on HIV replication, immune response, and cellular function.\n2. **miRNA Overexpression/Knockdown**: Use techniques like lentiviral transduction or siRNA-mediated knockdown to modulate miRNA expression in cells and assess the effects on HIV replication and cellular function.\n3. **High-Throughput Screening**: Utilize high-throughput screening approaches (e.g., microarray, next-generation sequencing) to identify miRNAs that are differentially expressed in response to HIV infection or antiretroviral therapy.\n\n**In Vivo Studies:**\n\n1. **Animal Models**: Use relevant animal models (e.g., humanized mice, non-human primates) to study the effects of miRNA modulation on HIV infection and disease progression.\n2. **miRNA Delivery**: Develop and test miRNA-based therapeutics (e.g., miRNA mimics, antagomirs) in animal models to assess their efficacy and safety.\n\n**Clinical Studies:**\n\n1. **Patient Samples**: Collect and analyze blood or tissue samples from HIV-infected individuals to study miRNA expression and its correlation with disease progression, immune response, and antiretroviral therapy response.\n2. **Longitudinal Studies**: Conduct longitudinal studies to investigate changes in miRNA expression over time in response to antiretroviral therapy or other interventions.\n3. **Clinical Trials**: Design and conduct clinical trials to test the safety and efficacy of miRNA-based therapeutics in HIV-infected individuals.\n\n**Bioinformatics and Computational Analysis:**\n\n1. **miRNA Target Prediction**: Use bioinformatics tools to predict the targets of selected miRNAs and identify potential off-target effects.\n2. **Network Analysis**: Analyze the miRNA regulatory networks in HIV-infected cells to identify key nodes and potential therapeutic targets.\n3. **Machine Learning**: Apply machine learning algorithms to integrate multi-omics data (e.g., genomics, transcriptomics, proteomics) to identify miRNA signatures associated with HIV disease progression and response to therapy.\n\n**Validation and Verification:**\n\n1. **Independent Validation**: Validate findings using independent datasets, experimental approaches, and study populations.\n2. **Mechanistic Studies**: Conduct mechanistic studies to elucidate the molecular mechanisms underlying the observed effects of miRNA modulation on HIV infection and disease progression.\n\nBy following this methodological framework, researchers can comprehensively investigate the role of miRNAs as therapeutic targets in HIV patients and develop effective miRNA-based interventions to improve treatment outcomes."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): What is known about DNA methylation profiles in pa
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nWhat is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?<|eot_id|>assistant\n\nDNA methylation is a crucial epigenetic modification that plays a significant role in regulating gene expression. In the context of HIV-1 infection, DNA methylation profiles have been studied to understand their impact on the virus's life cycle, latency, and disease progression. Here's a summary of what is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection:\n\n**Latent HIV-1 infection:**\n\n1. **Promoter methylation**: Studies have shown that the HIV-1 promoter region is hypermethylated in latently infected cells, which contributes to the silencing of viral transcription. This epigenetic modification helps to maintain latency by preventing the expression of viral genes.\n2. **Gene-specific methylation**: Specific genes involved in HIV-1 replication, such as the long terminal repeat (LTR) and the tat gene, are hypermethylated in latently infected cells. This targeted methylation helps to suppress viral transcription and maintain latency.\n3. **Histone modifications**: Latently infected cells often exhibit repressive histone modifications, such as histone 3 lysine 27 trimethylation (H3K27me3), which are associated with gene silencing.\n\n**Active HIV-1 infection:**\n\n1. **Hypomethylation**: In contrast to latent infection, actively infected cells exhibit hypomethylation of the HIV-1 promoter region, which leads to increased viral transcription and replication.\n2. **Global DNA hypomethylation**: Active HIV-1 infection is associated with global DNA hypomethylation, which can contribute to the activation of viral and host genes involved in the inflammatory response.\n3. **Gene-specific demethylation**: Specific genes involved in HIV-1 replication, such as the LTR and the env gene, are demethylated in actively infected cells, allowing for increased viral transcription and replication.\n\n**Comparison between latent and active infection:**\n\n1. **Methylation patterns**: The methylation patterns of latent and active HIV-1 infection are distinct, with latent infection characterized by hypermethylation and active infection by hypomethylation.\n2. **Epigenetic regulation**: The epigenetic regulation of HIV-1 gene expression is complex and involves the interplay between DNA methylation, histone modifications, and other epigenetic mechanisms.\n3. **Therapeutic implications**: Understanding the DNA methylation profiles of latent and active HIV-1 infection can inform the development of novel therapeutic strategies, such as epigenetic editing or the use of epigenetic modifiers to reactivate latent viruses or suppress active replication.\n\n**Limitations and future directions:**\n\n1. **Heterogeneity**: HIV-1 infection is characterized by significant heterogeneity, and DNA methylation profiles may vary between different cell types, tissues, and individuals.\n2. **Longitudinal studies**: Longitudinal studies are needed to investigate the dynamics of DNA methylation profiles over time and in response to antiretroviral therapy (ART).\n3. **Epigenetic editing**: The development of epigenetic editing tools, such as CRISPR-Cas9, may enable the precise manipulation of DNA methylation patterns to modulate HIV-1 gene expression and potentially cure the infection.\n\nIn summary, DNA methylation profiles play a crucial role in regulating HIV-1 gene expression, and distinct patterns are observed in latent and active infection. Further research is needed to elucidate the mechanisms underlying these epigenetic modifications and to explore their therapeutic potential."}
Saved Llama answers (category=3, iteration=1) to: /cluster/home/gcardenal/HIV/deploy_medical_LLM_evaluation/deploy_medical_llm_evaluation/model_answers/raw/Llama_cluster/Llama_answers_category_3.1_HIV_EQ.json
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 26-year-old female with AIDS (CD4 count: 47) pre
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nA 26-year-old female with AIDS (CD4 count: 47) presents to the emergency department in severe pain. She states that over the past week she has been fatigued and has had a progressively worse headache and fever. These symptoms have failed to remit leading her to seek care in the ED. A lumbar puncture is performed which demonstrates an opening pressure of 285 mm H2O, increased lymphocytes, elevated protein, and decreased glucose. The emergency physician subsequently initiates treatment with IV amphotericin B and PO flucytosine. What additional treatment in the acute setting may be warranted in this patient?<|eot_id|>assistant\n\nBased on the patient's presentation and laboratory results, it is likely that she has cryptococcal meningitis, a common opportunistic infection in patients with AIDS. The elevated opening pressure, increased lymphocytes, elevated protein, and decreased glucose in the cerebrospinal fluid (CSF) are consistent with this diagnosis.\n\nIn addition to the treatment with IV amphotericin B and PO flucytosine, which is appropriate for cryptococcal meningitis, the patient may also benefit from the following additional treatment in the acute setting:\n\n1. **Repeat lumbar punctures**: To relieve elevated intracranial pressure, which can be life-threatening. Repeat lumbar punctures may be necessary to remove excess CSF and reduce the pressure.\n2. **Corticosteroids**: Some guidelines recommend the use of corticosteroids, such as dexamethasone, to reduce inflammation and swelling in the brain, although this is not universally agreed upon.\n3. **Anticonvulsant prophylaxis**: Seizures can occur in patients with cryptococcal meningitis, so anticonvulsant prophylaxis may be considered.\n4. **Supportive care**: The patient may require supportive care, such as pain management, antipyretics, and hydration, to manage her symptoms and prevent complications.\n5. **Monitoring of renal function**: Amphotericin B can be nephrotoxic, so close monitoring of the patient's renal function is essential.\n\nIt's worth noting that the patient's CD4 count is very low, which puts her at high risk for other opportunistic infections and complications. Therefore, it's essential to consider other potential diagnoses and to monitor her closely for any signs of deterioration or new symptoms."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): You are reviewing raw data from a research study p
<class 'dict'> {'generated_text': "<|begin_of_text|><|start_header_id|>system<|end_header_id|>\n\nCutting Knowledge Date: December 2023\nToday Date: 26 Jul 2024\n\n<|eot_id|><|start_header_id|>user<|end_header_id|>\n\nYou are reviewing raw data from a research study performed at your medical center examining the effectiveness of a novel AIDS screening examination. The study enrolled 250 patients with confirmed AIDS, and 240 of these patients demonstrated a positive screening examination. The control arm of the study enrolled 250 patients who do not have AIDS, and only 5 of these patients tested positive on the novel screening examination. What is the NPV of this novel test?<|eot_id|>assistant\n\nTo calculate the Negative Predictive Value (NPV) of the novel AIDS screening examination, we first need to understand what NPV is. The NPV is the probability that subjects with a negative screening test truly don't have the disease. Mathematically, it is calculated as the number of true negatives (TN) divided by the sum of true negatives (TN) and false negatives (FN).\n\nGiven data:\n- Total patients with confirmed AIDS (and thus potentially false negatives if they test negative) = 250\n- Patients with AIDS who tested positive = 240\n- Therefore, patients with AIDS who tested negative (false negatives, FN) = 250 - 240 = 10\n- Total patients without AIDS (and thus potentially true negatives if they test negative) = 250\n- Patients without AIDS who tested positive (false positives, FP) = 5\n- Therefore, patients without AIDS who tested negative (true negatives, TN) = 250 - 5 = 245\n\nThe formula for NPV is: NPV = TN / (TN + FN)\n\nPlugging the numbers into the formula: NPV = 245 / (245 + 10) = 245 / 255\n\nCalculating the NPV: NPV = 245 / 255 ≈ 0.9608 or approximately 96.08%\n\nTherefore, the Negative Predictive Value of this novel AIDS screening test is approximately 96.08%. This means that about 96.08% of the patients who test negative are truly free of AIDS."}
API call for Llama failed with error: Connection error.
Starting inference for question locally (Llama): A 46-year-old Caucasian male with past medical his
slurmstepd: error: *** STEP 21058700.0 ON eu-a65-06 CANCELLED AT 2025-01-17T14:19:45 ***
slurmstepd: error: *** JOB 21058700 ON eu-a65-06 CANCELLED AT 2025-01-17T14:19:45 ***
W0117 14:19:45.582000 22693303187264 torch/distributed/elastic/agent/server/api.py:741] Received 15 death signal, shutting down workers
W0117 14:19:45.582000 22693303187264 torch/distributed/elastic/multiprocessing/api.py:851] Sending process 2880170 closing signal SIGTERM
